# Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study

> **NCT04327232** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 184 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Spironolactone 25mg
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04327232
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-23
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2020-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04327232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04327232, "Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04327232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*